Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Probiotic Supplementation With BLa80, BL21, and LRa05 Stabilizes Lipid Metabolism in Chronic Hepatitis B Patients Receiving Tenofovir Alafenamide: A Clinical Trial

NCT06221605 is registered in ClinicalTrials.gov with Wecare Probiotics Co., Ltd. as lead sponsor.

NCT NCT06221605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06221605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Probiotic Supplementation With BLa80, BL21, and LRa05 Stabilizes Lipid Metabolism in Chronic Hepatitis B Patients Receiving Tenofovir Alafenamide: A Clinical Trial
Lead sponsor
Wecare Probiotics Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
March 30, 2024
Completion date
April 11, 2025
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b